10-Q 1 skin0504form10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2017

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___ to ___

 

Commission file number: 000-30991

 

SKINOVATION PHARMACEUTICAL INCORPORATED

(Exact name of registrant as specified in its charter)

Wyoming

(State or other jurisdiction of incorporation or organization)

87-0458170

(I.R.S. Employer Identification No.)

2157 S. Lincoln Street, Salt Lake City, Utah

(Address of principal executive offices)

84106

(Zip Code)

(801) 323-2395

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐ The registrant does not have a Web site.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Non-accelerated filer ☐

Emerging growth company ☑

Accelerated filer ☐

Smaller reporting company ☑

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☑ No ☐

 

The number of shares outstanding of the registrant’s common stock as of May 5, 2017 was 708,000.

 
 

TABLE OF CONTENTS

 

  PART I – FINANCIAL INFORMATION  
     
Item 1. Financial Statements (Unaudited) 2
Condensed Balance Sheets (Unaudited) 3
  Condensed Statements of Operations (Unaudited) 4
  Condensed Statements of Cash Flows (Unaudited) 5
  Notes to the Unaudited Condensed Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 7
Item 3. Quantitative and Qualitative Disclosures about Market Risk 9
Item 4. Controls and Procedures 9
     
  PART II – OTHER INFORMATION  
     
Item 6. Exhibits 10
Signatures 11

 

 

 

 

 

 

 

 

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

 

 

 

SKINOVATION PHARMACEUTICAL INCORPORATED

 

Condensed Financial Statements

 

March 31, 2017

 

(Unaudited)

 

 2 

 

Skinovation Pharmaceutical Incorporated

Condensed Balance Sheets

(Unaudited)

 

       
  

MAR 31,

2017

 

DEC 31,

2016

       
ASSETS      
Current Assets      
Cash  $262   $277 
Total Current Assets   262    277 
Total Assets  $262   $277 
           
LIABILITIES AND STOCKHOLDERS' DEFICIT          
Current Liabilities          
Accounts payable  $12,400   $6,900 
Notes payable   172,521    172,521 
Accrued interest   52,761    49,311 
Total Current Liabilities   237,682    228,732 
Total Liabilities   237,682    228,732 
Stockholders' Deficit          
Preferred stock, $.001 par value; 25,000,000 shares
authorized; 0 shares issued and outstanding
   —      —   
Common stock, $.001 par value; 50,000,000 shares
authorized; 708,000 shares issued and outstanding
   708    708 
Additional paid in capital   25,148    25,148 
Accumulated deficit   (263,276)   (254,311)
Total Stockholders' Deficit   (237,420)   (228,455)
Total Liabilities and Stockholders' Deficit  $262   $277 

  

The accompanying notes are an integral part of these financial statements.

 

 3 

 

Skinovation Pharmaceutical Incorporated

Condensed Statements of Operations

(Unaudited)

 

   FOR THE
THREE MONTHS
ENDED
MAR 31,
2017
  FOR THE
THREE MONTHS
ENDED
MAR 31,
2016
       
REVENUES  $—     $—   
           
EXPENSES          
General and administrative   5,515    6,230 
TOTAL EXPENSES   5,515    6,230 
           
INCOME (LOSS) BEFORE OTHER EXPENSE   (5,515)   (6,230)
           
OTHER INCOME (EXPENSE)          
Interest expense   (3,450)   (3,140)
Total other income (expense)   (3,450)   (3,140)
           
INCOME (LOSS) BEFORE INCOME TAXES   (8,965)   (9,370)
           
INCOME TAXES   —      —   
           
NET INCOME (LOSS)  $(8,965)  $(9,370)
           
Basic and diluted net income (loss) per share  $(0.01)  $(0.04)
           
Weighted average shares outstanding   708,000    708,000 

 

The accompanying notes are an integral part of these financial statements.

 

 4 

 

Skinovation Pharmaceutical Incorporated

Condensed Statements of Cash Flows

(Unaudited)

 

   FOR THE THREE
MONTHS ENDED
MAR 31,
2017
  FOR THE THREE MONTHS ENDED
MAR 31,
2016
           
Cash Flows from Operating Activities          
Net income (loss)  $(8,965)  $(9,370)
Adjustments to reconcile net loss to cash used by
operating activities:
          
Changes in assets and liabilities:          
Increase (decrease) in accounts payable   5,500    5,100 
Increase in accrued interest   3,450    3,140 
Net cash used by operating activities   (15)   (1,130)
           
Cash Flows from Investing Activities          
Net cash used by investing activities   —      —   
           
Cash Flows from Financing Activities          
Proceeds from notes payable   —      4,600 
Net cash provided by financing activities   —      4,600 
           
           
Increase (decrease) in cash   (15)   3,470 
           
Cash and cash equivalents at beginning of period   277    302 
           
Cash and cash equivalents at end of period  $262   $3,772 

 

The accompanying notes are an integral part of these financial statements.

 

 5 

 

Skinovation Pharmaceutical Incorporated

Notes to the Unaudited Condensed Financial Statements

March 31, 2017

 

NOTE 1 – Condensed Financial Statements

 

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of and for the period ended March 31, 2017 and for all periods presented have been made.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2016 audited financial statements as reported in its Form 10-K. The results of operations for the period ended March 31, 2017 are not necessarily indicative of the operating results for the full year ended December 31, 2017.

 

NOTE 2 – Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has limited assets, has incurred losses since inception, has negative cash flows from operations, and has no revenue-generating activities. Its activities have been limited for the past several years and it is dependent upon financing to continue operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. It is management’s plan to acquire or merge with other operating companies.

 

NOTE 3 – Subsequent Events

 

The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and has determined that there are no such events that would have a material impact on the financial statements.

 

 6 

 

In this report references to “Skinovation,” “we,” “us,” and “our” refer to Skinovation Pharmaceutical Incorporated.

 

FORWARD LOOKING STATEMENTS

 

The U. S. Securities and Exchange Commission (“SEC”) encourages reporting companies to disclose forward-looking information so that investors can better understand future prospects and make informed investment decisions. This report contains these types of statements. Words such as “may,” “expect,” “believe,” “intend,” “anticipate,” “estimate,” “project,” or “continue” or comparable terminology used in connection with any discussion of future operating results or financial performance identify forward-looking statements. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. All forward-looking statements reflect our present expectation of future events and are subject to a number of important factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Executive Overview

 

We have not recorded revenues for the past two fiscal years and we are dependent upon financing to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one is obligated to provide funds to us in the future. These factors raise doubt as to our ability to continue as a going concern. Our plan is to combine with an operating company to generate revenue.

 

As of the date of this report, our management has not had any discussions with any representative of any other entity regarding a business combination with us. Any target business that is selected may be a financially unstable company or an entity in its early stages of development or growth, including entities without established records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially unstable and early stage or potential emerging growth companies. In addition, we may effect a business combination with an entity in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution to present stockholders of the Company.

 

We anticipate that the selection of a business opportunity will be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available business combinations may occur in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex.

 

If we obtain a business opportunity, then it may be necessary to raise additional capital. We anticipate that we will sell our common stock to raise this additional capital. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.

 

 7 

 

Liquidity and Capital Resources

 

We have not recorded revenues from operations during 2017 and 2016 and have not established an ongoing source of revenue sufficient to cover our operating costs. We expect to rely upon third parties to pay for our operating expenses. At March 31, 2017 we had cash of $262 compared to $277 cash at December 31, 2016. Our total liabilities increased to $237,682 at March 31, 2017 from $228,732 at December 31, 2016. The increase in total liabilities is primarily due to increases in accounts payable, accrued interest and consulting services and professional services provided by, or paid for by, third parties.

 

We intend to obtain capital from management, significant stockholders and third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability for the long term.

 

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through advances and loans provided by management, significant stockholders or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses.

 

Results of Operations

 

We did not record revenues in 2017 or 2016. General and administrative expense decreased to $5,515 for the 2017 first quarter compared to $6,230 for the 2016 first quarter. The decrease in general and administrative expense primarily represents reduced professional and consulting services required for our operations.

 

Total other expense representing accrued interest on notes payable increased to $3,450 for the 2017 first quarter compared to $3,140 for the 2016 first quarter.

 

Our net loss decreased to $8,965 for the 2017 first quarter compared to $9,370 for the 2016 first quarter. Management expects net losses to continue until we acquire or merge with a business opportunity.

 

Commitments and Obligations

 

At March 31, 2017 we had outstanding notes payable totaling $172,521. All of the notes payable are non-collateralized, carry interest at 8% and are due on demand. We recorded accrued interest of $3,450 for the notes payable for the 2017 first quarter and recorded total accrued interest at March 31, 2017 of $52,761.

 

During the 2017 first quarter we incurred $9,000 in accounts payable for consulting services and professional services provided by, or paid for by, third parties. We also owe vendors $3,400 at March 31, 2017.

 

Two lenders represent in excess of 95% of the Company’s accounts payable and notes payable at March 31, 2017.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

 8 

 

Critical Accounting Policies

 

We qualify as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements. For so long as we are an emerging growth company, among other things, we will not be required to:

 

Have an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;

 

Submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay” and “say-on-frequency”

 

Obtain shareholder approval of any golden parachute payments not previously approved; and

 

Disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the Chief Executives compensation to median employee compensation.

 

In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards.

 

We will remain an “emerging growth company” for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1 billion; (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed third fiscal quarter or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable to smaller reporting companies.

 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Our President, who serves as our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and he determined that our disclosure controls and procedures were ineffective due to a control deficiency. During the period we did not have additional personnel to allow segregation of duties to ensure the completeness or accuracy of our information. Due to the size and operations of the Company we are unable to remediate this deficiency until we acquire or merge with another company.

 

Changes to Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an evaluation of our internal control over financial reporting and determined that there were no changes made in our internal control over financial reporting during the quarter ended March 31, 2017 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

 9 

 

PART II – OTHER INFORMATION

 

ITEM 6. EXHIBITS

 

Part I Exhibits

No. Description
31.1 Principal Executive Officer Certification
31.2 Principal Financial Officer Certification
32.1 Section 1350 Certification

 

Part II Exhibits

No. Description
3(i)

Wyoming Articles of Domestication, filed November 23, 2016 (Incorporated by reference to exhibit 3(i).2 of Form 10-K, filed March 20, 2017)

3(ii)

Bylaws of Skinovation (Incorporated by reference to exhibit 3(ii) of Form 10-K, filed March 20, 2017)

101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Label Linkbase Document
101.PRE XBRL Taxonomy Presentation Linkbase Document

 

 10 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

Date: May 11, 2017

SKINOVATION PHARMACEUTICAL INCORPORATED

 

 

By:       /s/ Hugo Rodier

Hugo Rodier

President and Director

Principal Financial Officer

 

 

11